Abstract #0543

Hemodynamic imaging in brain tumors using dextran1-enhanced CEST MRI

Chuheng Chen¹, Zheng Han², Xiang Xu^2,3, Renyuan Bai⁴, Verena Staedtke⁴, Jiadi Xu^2,3, Linda Knutsson^2,5, Peter van Zijl^2,3, and Guanshu Liu^2,3

¹Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, United States, ²Department of Radiology, Johns Hopkins University, Baltimore, MD, United States, ³F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, United States, ⁴Department of Oncology, Johns Hopkins University, Baltimore, MD, United States, ⁵Department of Medical Radiation Physics, Lund University, Lund, Sweden

Sugar-based compounds have shown potential as biodegradable contrast agents for cancer detection. Recently, a multi-size dextran MRI approach was developed for detecting permeability-related properties in tumors. Here, we explored a small size dextran, dextran1 (MW~ 1 kD), as a new MRI contrast agent for detecting brain tumor hemodynamic properties including blood–brain barrier (BBB) breakdown and cerebral blood volume. Our results demonstrate that dextran1 has great potential in indicating BBB integrity, which is confirmed by dynamic contrast-enhanced (DCE) MRI and histology findings. Importantly, contrary to D-glucose, dextran1 does not enter the CSF, removing a source of interfering background signal that is present in dynamic glucose-enhanced (DGE) MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here